Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N96
- Lead Sponsor
- ???? ????? ?????
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcoholism and Narcoticism
History of allergy to Linagliptin&Empagliflozin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug plasma concentration. Timepoint: 0? 0.5? 1? 1.5? 2? 2.5? 0?3? 3.5? 4.0? 6.0? 8.0? 10? 12? 24? 48 , 72 after drug administration. Method of measurement: Liquid Chromatography Mass-Mass.
- Secondary Outcome Measures
Name Time Method En Time to reach maximum plasma concentration. Timepoint: En After intervention. Method of measurement: En Time to reach the maximum drug concentration in plasma is recorded.;En Extent of absorption. Timepoint: En After intervention. Method of measurement: En Calculation of area under curve of concentration -time.